Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

August 21, 2020 Bioscience

Clinton’s Ce3 merges with North Carolina firm

PHOTO | Contributed Holly Coulter
By Natalie Missakian

A Clinton company that contracts with biotechnology firms to provide clinical trial design and management services has merged with a North Carolina company.

Wilmington, N.C.-based Catalyst Clinical Research announced the marriage with Clinton’s Ce3 Inc. earlier this month. 

The newly merged company will be headquartered in Wilmington but retain the Clinton office, giving it a Northeast presence, Catalyst said. Financial terms of the deal were not disclosed.

Both companies are contract research organizations (CROs) for the biopharmaceutical industry. 

Catalyst said it merged with Ce3 as a way to expand its “depth of oncology-specific therapeutic expertise.” 

The union creates a company with particular expertise “working with biotech sponsors on complex cancer therapies and study designs,” Catalyst said in a statement.

Ce3 has specialized in oncology since it was founded in 2005. In a statement, Holly Coulter and Tim Garrelts, co-founders of the company, said the merger reinforces their commitment to being “a premier provider of early phase oncology clinical development services.”

They added that they were “excited to leverage Catalyst’s additional technology offerings, geographic footprint and global network of clinical research professionals.”

Contact Natalie Missakian at news@newhavenbiz.com

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF